Innovations Needed and Future Directions in Treatment of NSCLC

EP: 1.CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC

EP: 2.Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy

EP: 3.Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023

EP: 4.Lessons from LIBRETTO-431 Trial in RET+ NSCLC

EP: 5.PAPILLON Trial Insights: ESMO 2023

Now Viewing

EP: 6.Innovations Needed and Future Directions in Treatment of NSCLC

This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.

Forde summarizes that significant advances have been made in non–small cell lung cancer (NSCLC), especially in the first-line setting for advanced disease and increasingly for early-stage disease with neoadjuvant immunotherapy. He notes further work is needed to improve outcomes for early-stage patients without a pathologic complete response to neoadjuvant therapy. Additional adjuvant targeted therapy trials are warranted in oncogene-driven NSCLC subtypes beyond EGFR and ALK.

In advanced NSCLC, numerous first-line options now exist, but second-line options remain very limited following first-line chemoimmunotherapy. Forde discusses the inconclusive TROPION-LUNG01 (NCT04656652) study in a novel postchemoimmunotherapy second-line setting. Clearly more work is needed in the second-line advanced setting.

In first-line EGFR-mutant advanced NSCLC, Forde notes the MARIPOSA trial (NCT04487080) showed improved progression-free survival with amivantamab-nazartinib vs osimertinib, but toxicity was increased, so more data are needed before practice changes. In contrast, the second-line MARIPOSA-2 trial (NCT04988295) supports adding amivantamab to chemotherapy vs chemotherapy alone post osimertinib, given the HR of 0.44 favoring the combination. However, toxicity requires monitoring with amivantamab-containing regimens.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.